ORIGINAL RESEARCH article
Front. Vet. Sci.
Sec. Veterinary Dentistry and Oromaxillofacial Surgery
Volume 12 - 2025 | doi: 10.3389/fvets.2025.1656782
This article is part of the Research TopicRecent Advances in Oral Medicine in Dogs and CatsView all 8 articles
Cathepsin K Inhibition by VBX1000 Alleviates Canine Periodontitis
Provisionally accepted- 124-hour veterinary clinic Arka, Krakow, Poland
- 2Klinika Weterynaryjna Arka, Kraków, Poland
- 3Alliance, Bordeaux, France
- 4Clinique Veterinaire, Mirambeau, France
- 5Veterinary clinic, Warsaw, Poland
- 6Veterinary clinic, Lodz, Poland
- 7Vetbiolix, Loos, France
- 8OCRvet, Lille, France
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The efficacy and safety of a novel Cathepsin K inhibitor, VBX1000, were evaluated in client-owned dogs suffering from periodontal disease. This open-label study recruited twenty dogs (n=20) with at least 3 teeth at stage 2 or 3 of periodontal disease. Dogs were orally treated once-a-day with VBX1000 (25 mg/kg or 50 mg/kg, n=10 per group) for 60 days, and then with 50 mg/kg once-a-day for an additional 30 days. The first objective was to assess evolution compared to pre-treatment of plasma carboxy-terminal telopeptide of collagen type 1 (CTX1) used as a marker of target engagement and bone resorption. In each evaluated tooth (n=60; three teeth per dog), evolution counter to baseline of clinical attachment loss (CAL), periodontal probing depth (PPD), and bleeding on probing index (BPI) were evaluated The effects of Cathepsin K inhibitor on alveolar bone defects were assessed with intraoral dental radiography (DR) performed at inclusion and at the end of the treatment period. A confirmatory analysis was performed in a subpopulation (n=10 dogs; 30 teeth) using the cone beam computed tomography scan (CBCT) imaging technique. Throughout the treatment period, VBX1000 was well tolerated. At Day60, plasma CTX1 was significantly and similarly reduced compared with baseline (p<0.05) in the two groups. At the end of the treatment period (at Day90) in the total population (n=20), plasma CTX1 was 0.10±0.04 ng/mL relative to 0.26±0.20 ng/mL at baseline (p<0.001). DR before and after treatment showed decreases in width (n=60 teeth; three teeth/dog; p<0.0001), depth (p<0.05), and height of bone defects measured between the root and the maxillary bone. These effects on bone defects were confirmed in a subpopulation analyzed by CBCT. At the end of the treatment period, clinical attachment loss (CAL) was reduced relative to pretreatment: 2.87±1.73 mm compared to 3.86±2.06 mm (n=60; p<0.0001). Likewise, the periodontal probing depth (PPD) was reduced 2.71±1.03 mm compared to 3.69±1.23 mm (n=60, p<0.0001). Conclusion: The findings support the inhibition of cathepsin K by VBX1000 as a new therapeutic approach for mild-to-moderate periodontal disease in dogs. A randomized, double blinded placebo-controlled trial in dogs should confirm the potential of VBX1000 in this indication.
Keywords: Cathepsin K, Canine periodontitis, open-label study, Safety, efficacy, VBX-1000
Received: 30 Jun 2025; Accepted: 02 Oct 2025.
Copyright: © 2025 Gawor, Ziemann, Druet, Salindre, Gajosz, Kowalczyk, Dam, Tierny, Dubruque and Hanf. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jerzy Pawel Gawor, jgawor@pp.com.pl
Remy Hanf, remy.hanf@vetbiolix.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.